Currently, targeted protein degradation (TPD) has become a groundbreaking strategy in drug discovery. This approach is emerging as a novel therapeutic method to aim at diseases such as cancer, inflammatory and immune diseases and infections, as many of them are driven by the aberrant expression of a pathogenic protein. TPD involves recruiting disease-causing proteins previously thought to be "undruggable" due to their lack of canonical ligand binding sites for rapid destruction and elimination via the ubiquitin-proteasome pathway. The ubiquitin-proteasome system (UPS) is a major mechanism for cellular protein degradation and maintaining protein homeostasis, as part of the regular cellular housekeeping processes. Thus, the potential breadth of TPD applications is almost unlimited.